Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
June 14, 2017 7:00 am
Briefly noted: C Ma et al. Inflamm Bowel Dis 2017; 23: 833-9. This retrospective study examined the response to ustekinumab in 104 patients with Crohn’s disease. All patients had achieved a steroid-free ustekinumab induction. 92.3% had failed anti-TNFα therapy.
Key findings:
Posted by gutsandgrowth
Categories: inflammatory bowel disease
Tags: ustekinumab
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
Didn’t read the article yet, but impressive response rate for anti-TNF failures. I don’t think we have seen that with any other biologic post anti-TNF failure?
By Benjamin Enav on June 14, 2017 at 8:19 am
One reason for the impressive results was that all had undergone an ustekinumab induction and therefore had already responded. This study shows mainly that if one responds to ustekinumab, they are likely to maintain a response.
By gutsandgrowth on June 14, 2017 at 8:30 am
[…] More Data for Ustekinumab in Crohn’s Disease […]
By Ustekinumab for Ulcerative Colitis (UNIFI Trial) | gutsandgrowth on October 2, 2019 at 7:02 am
[…] More Data for Ustekinumab in Crohn’s Disease […]
By Dose Escalation of Ustekinumab & Support Tool “Should I Have IBD Surgery?” | gutsandgrowth on April 11, 2020 at 8:59 am